About Xenia 25 | Uses of Xenia 25 | Medical Dialogues

Xenia 25 is a sodium-glucose cotransporter-2 (SGLT2) inhibitor containing 25 mg of empagliflozin. It is marketed by USV Private Limited. Empagliflozin reduces blood glucose levels by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. The 25 mg dose of empagliflozin in clinical trials has shown enhanced glycemic efficacy and additional cardiovascular and renal protective effects.

For more info: https://medicaldialogues.in/medicines/xenia-25-2728207